Deregulated protein tyrosine kinase activity is central to the pathogenesis of human cancers.
Targeted therapy in the form of selective tyrosine kinase inhibitors (TKIs) has transformed …

Cancer drug resistance continues to be a major impediment in medical oncology. Clinically,
resistance can arise prior to or as a result of cancer therapy. In this review, we discuss …

Purpose We report the 5-year analysis from the phase III Dasatinib Versus Imatinib Study in
Treatment-Naïve Chronic Myeloid Leukemia Patients (DASISION) trial, evaluating long-term …

Purpose To review and update the European LeukemiaNet (ELN) recommendations for the
management of chronic myeloid leukemia with imatinib and second-generation tyrosine …

Abstract Mutations in the Bcr-Abl kinase domain may cause, or contribute to, resistance to
tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia patients. Recommendations …

Chronic myeloid leukemia (CML) has been regarded as the paradigmatic example of a
malignancy defined by a unique molecular event, the BCR-ABL1 oncogene. Decades of …

Genomic events associated with poor outcome in chronic myeloid leukemia (CML) are
poorly understood. We performed whole-exome sequencing, copy-number variation, and/or …

The introduction of selective tyrosine-kinase inhibitors (TKIs) for the treatment of chronic
myeloid leukaemia has changed patient outcome and, consequently, management of this …

Imatinib at 400 mg daily is standard treatment for chronic myeloid leukemia in chronic
phase. We here describe the correlation of imatinib trough plasma concentrations (Cmins) …

Chronic Myeloid Leukemia (CML) is a clonal disease characterized by the presence of the
Philadelphia (Ph+) chromosome and its oncogenic product, BCR-ABL, a constitutively active …